Nuvectis Gets FDA Fast-Track Designation for NXP800 in Ovarian Cancer

By Colin Kellaher

Nuvectis Pharma Inc. on Thursday said the U.S. Food and Drug Administration granted fast-track designation to its NXP800 drug candidate in a form of ovarian cancer.

The Fort Lee, N.J., biopharmaceutical company said the designation covers NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

12-01-22 0830ET